China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Other Current Liabilities: ¥349 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600062 China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
90 GF Score
Price ¥16.63
GF Value ¥18.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China Resources Double-Crane Pharmaceutical Co Other Current Liabilities?

China Resources Double-Crane Pharmaceutical Co SHSE:600062 -2.81% 90 Other Current Liabilities is ¥349 Mil as of Mar. 2026. GuruFocus rates SHSE:600062 with a GF Score™ of 90/100 and a GF Value™ of ¥18.83 (Modestly Undervalued). The stock has 4 warning signs investors should review.

China Resources Double-Crane Pharmaceutical Co's other current liabilities for the quarter that ended in Mar. 2026 was ¥349 Mil.

China Resources Double-Crane Pharmaceutical Co's quarterly other current liabilities increased from Sep. 2025 (¥156 Mil) to Dec. 2025 (¥212 Mil) and increased from Dec. 2025 (¥212 Mil) to Mar. 2026 (¥349 Mil).

China Resources Double-Crane Pharmaceutical Co's annual other current liabilities declined from Dec. 2023 (¥319 Mil) to Dec. 2024 (¥188 Mil) but then increased from Dec. 2024 (¥188 Mil) to Dec. 2025 (¥212 Mil).

China Resources Double-Crane Pharmaceutical Co Other Current Liabilities Related Terms

China Resources Double-Crane Pharmaceutical Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for China Resources Double-Crane Pharmaceutical Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Double-Crane Pharmaceutical Co Other Current Liabilities Chart

China Resources Double-Crane Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 258.56 251.78 319.37 187.80 211.83

China Resources Double-Crane Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 242.44 159.66 155.74 211.83 348.65
SHSE:600062
90GF Score
China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Double-Crane Pharmaceutical Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ¥349 Mil mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Other Current Liabilities of ¥349 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on China Resources Double-Crane Pharmaceutical Co.
Is China Resources Double-Crane Pharmaceutical Co's Other Current Liabilities too high?
China Resources Double-Crane Pharmaceutical Co's current Other Current Liabilities is ¥349 Mil. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Other Current Liabilities compare to ZTS and UTHR?
China Resources Double-Crane Pharmaceutical Co's Other Current Liabilities of ¥349 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on China Resources Double-Crane Pharmaceutical Co. China Resources Double-Crane Pharmaceutical Co's current Other Current Liabilities is ¥349 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.83, compared to a current price of ¥16.63 — trading 11.7% below its estimated fair value. The current Other Current Liabilities is ¥349 Mil. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Other Current Liabilities is ¥349 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.63 is trading 11.7% below its estimated GF Value™ of ¥18.83. GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600062:

  • Other Current Liabilities: ¥349 Mil
  • GF Value™: ¥18.83 vs. price of ¥16.63 (11.7% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Double-Crane Pharmaceutical Co Business Description

Address No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score

Get the complete analysis for SHSE:600062

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.63
Price
¥18.83
GF Value